Difference between revisions of "Therapeutic equivalents"
Jump to navigation
Jump to search
m (→Same class) |
m (→Biosimilars) |
||
| Line 4: | Line 4: | ||
=Categories of therapeutically equivalent drugs= | =Categories of therapeutically equivalent drugs= | ||
| + | ==Recombinant proteins== | ||
| + | These are identical products to a parent natural protein, which are created through synthetic methods. | ||
| + | {| class="wikitable sortable" style="width: 50%; text-align:center;" | ||
| + | ! style="width: 50%" |Parent compound | ||
| + | ! style="width: 50%" |Biosimilar(s) | ||
| + | |- | ||
| + | |[[Asparaginase Erwinia chrysanthemi (Erwinaze)]] | ||
| + | |[[Asparaginase erwinia chrysanthemi-rywn (Rylaze)]] | ||
| + | |- | ||
| + | |} | ||
| + | |||
==Biosimilars== | ==Biosimilars== | ||
| + | These are "nearly identical" products to a parent compound, with what is considered interchangeable efficacy and toxicity. | ||
| + | |||
| + | {| class="wikitable sortable" style="width: 75%; text-align:center;" | ||
| + | ! style="width: 33%" |Class of agent | ||
| + | ! style="width: 33%" |Parent compound | ||
| + | ! style="width: 33%" |Biosimilar(s) | ||
| + | |- | ||
| + | |Anti-VEGF antibody | ||
| + | |[[Bevacizumab (Avastin)]] | ||
| + | |[[Bevacizumab-adcd (Vegzelga)]]<br>[[Bevacizumab-awwb (Mvasi)]]<br>[[Bevacizumab-bvzr (Zirabev)]]<br>Bevacizumab (Alymsys/Oyavas)<br>Bevacizumab (Aybintio)<br>Bevacizumab (Equidacent)<br>Bevacizumab (Onbevzi) | ||
| + | |- | ||
| + | |Anticoagulant | ||
| + | |[[Enoxaparin (Lovenox)]] | ||
| + | |Enoxaparin (Inhixa) | ||
| + | |- | ||
| + | |Red cell growth factor | ||
| + | |[[Epoetin alfa (Procrit)]] | ||
| + | |[[Epoetin alfa-epbx (Retacrit)]]<br>Epoetin alfa (Abseamed)<br>Epoetin alfa (Binocrit)<br>Epoetin alfa (Epoetin Alfa Hexal) | ||
| + | |- | ||
| + | |Red cell growth factor | ||
| + | |Epoetin zeta (Eprex) | ||
| + | |Epoetin zeta (Silapo) | ||
| + | |- | ||
| + | |Myeloid growth factor | ||
| + | |[[Filgrastim (Neupogen)]] | ||
| + | |[[Filgrastim-aafi (Nivestym)]]<br>[[Filgrastim-sndz (Zarxio)]]<br>Filgrastim (Accofil)<br>Filgrastim (Filgrastim Hexal)<br>Filgrastim (Grastofil)<br>Filgrastim (Ratiograstim)<br>Filgrastim (Tevagrastim) | ||
| + | |- | ||
| + | |Myeloid growth factor | ||
| + | |[[Pegfilgrastim (Neulasta)]] | ||
| + | |[[Pegfilgrastim-apgf (Nyvepria)]]<br>[[Pegfilgrastim-bmez (Ziextenzo)]]<br>[[Pegfilgrastim-cbqv (Udenyca)]]<br>[[Pegfilgrastim-jmdb (Fulphila)]]<br>Pegfilgrastim (Cegfila)<br>Pegfilgrastim (Grasustek)<br>Pegfilgrastim (Pelgraz)<br>Pegfilgrastim (Pelmeg) | ||
| + | |- | ||
| + | |Anti-CD20 antibody | ||
| + | |[[Rituximab (Rituxan)]] | ||
| + | |[[Rituximab-abbs (Truxima)]]<br>[[Rituximab-arrx (Riabni)]]<br>[[Rituximab-pvvr (Ruxience)]]<br>Rituximab (Blitzima)<br>Rituximab (Ritemvia)<br>Rituximab (Rixathon)<br>Rituximab (Riximyo) | ||
| + | |- | ||
| + | |Anti-HER2 antibody | ||
| + | |[[Trastuzumab (Herceptin)]] | ||
| + | |[[Trastuzumab-anns (Kanjinti)]]<br>[[Trastuzumab-dkst (Ogivri)]]<br>[[Trastuzumab-dttb (Ontruzant)]]<br>[[Trastuzumab-pkrb (Herzuma)]]<br>[[Trastuzumab-qyyp (Trazimera)]]<br>Trastuzumab (Zercepac) | ||
| + | |- | ||
| + | |} | ||
==Same drug, different route== | ==Same drug, different route== | ||
Revision as of 00:13, 25 October 2022
This page is very much under construction at the moment.
Introduction
Generally speaking, prospective clinical trials are very specific in the drugs that they use in their evaluation. In clinical practice, one drug is often substituted for another, using the clinical concept of therapeutic equivalence. The purpose of this page is to gather various categories of therapeutic equivalence for general reference, and also to inform the HemOnc ontology. Please keep checking back as the page develops!
Categories of therapeutically equivalent drugs
Recombinant proteins
These are identical products to a parent natural protein, which are created through synthetic methods.
| Parent compound | Biosimilar(s) |
|---|---|
| Asparaginase Erwinia chrysanthemi (Erwinaze) | Asparaginase erwinia chrysanthemi-rywn (Rylaze) |
Biosimilars
These are "nearly identical" products to a parent compound, with what is considered interchangeable efficacy and toxicity.
| Class of agent | Parent compound | Biosimilar(s) |
|---|---|---|
| Anti-VEGF antibody | Bevacizumab (Avastin) | Bevacizumab-adcd (Vegzelga) Bevacizumab-awwb (Mvasi) Bevacizumab-bvzr (Zirabev) Bevacizumab (Alymsys/Oyavas) Bevacizumab (Aybintio) Bevacizumab (Equidacent) Bevacizumab (Onbevzi) |
| Anticoagulant | Enoxaparin (Lovenox) | Enoxaparin (Inhixa) |
| Red cell growth factor | Epoetin alfa (Procrit) | Epoetin alfa-epbx (Retacrit) Epoetin alfa (Abseamed) Epoetin alfa (Binocrit) Epoetin alfa (Epoetin Alfa Hexal) |
| Red cell growth factor | Epoetin zeta (Eprex) | Epoetin zeta (Silapo) |
| Myeloid growth factor | Filgrastim (Neupogen) | Filgrastim-aafi (Nivestym) Filgrastim-sndz (Zarxio) Filgrastim (Accofil) Filgrastim (Filgrastim Hexal) Filgrastim (Grastofil) Filgrastim (Ratiograstim) Filgrastim (Tevagrastim) |
| Myeloid growth factor | Pegfilgrastim (Neulasta) | Pegfilgrastim-apgf (Nyvepria) Pegfilgrastim-bmez (Ziextenzo) Pegfilgrastim-cbqv (Udenyca) Pegfilgrastim-jmdb (Fulphila) Pegfilgrastim (Cegfila) Pegfilgrastim (Grasustek) Pegfilgrastim (Pelgraz) Pegfilgrastim (Pelmeg) |
| Anti-CD20 antibody | Rituximab (Rituxan) | Rituximab-abbs (Truxima) Rituximab-arrx (Riabni) Rituximab-pvvr (Ruxience) Rituximab (Blitzima) Rituximab (Ritemvia) Rituximab (Rixathon) Rituximab (Riximyo) |
| Anti-HER2 antibody | Trastuzumab (Herceptin) | Trastuzumab-anns (Kanjinti) Trastuzumab-dkst (Ogivri) Trastuzumab-dttb (Ontruzant) Trastuzumab-pkrb (Herzuma) Trastuzumab-qyyp (Trazimera) Trastuzumab (Zercepac) |
Same drug, different route
(e.g., IV and SC daratumumab)
Combinations of agents
(e.g., Phesgo is combined pertuzumab & trastuzumab)
Enantiomers and racemic mixtures
Pro-drugs
(e.g., capecitabine & 5-FU, although this is tricky because of LCV...)
Same class
(e.g., cisplatin and carboplatin)